Cited by 291Colorectal Cancer Treatments and StudiesLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

Prenen, Hans, De Schutter, Jef, Jacobs, Bart, De Roock, Wendy, Biesmans, Bart, Claes, Bart, Lambrechts, Diether, Van Cutsem, Eric, Tejpar, Sabine·2009·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-08-2961

Open this paper in CoChat — free account

Abstract

Purpose: It has been reported that activating KRAS mutations negatively affect response to anti–epidermal growth factor receptor (EGFR) monoclonal antibodies in metastatic colorectal cancer. The mutation status of signaling molecules downstream of the EGFR target is thus crucial to predict clinical benefit to EGFR-targeted therapies. Other mechanisms of resistance to EGFR inhibitors could involve activating mutations of the other main EGFR effector pathway, i.e., the PI3K/PTEN/AKT pathway. Experimental Design: We analyzed the PIK3CA and KRAS mutation status in a large group (n = 200) of chemorefractory metastatic colorectal cancers treated with cetuximab (Erbitux) in monotherapy or in combination with irinotecan, and correlated the mutation status with outcome. Results: Twenty-three (12%) of the 200 samples carried 1 of the PIK3CA mutations included in our assay. We found no correlation between the presence of a PIK3CA mutation and impaired response to cetuximab. Conclusions: Our findings do not provide any evidence for a strong role of PIK3CA mutations as a single marker in determining response to cetuximab in chemorefractory metastatic colorectal cancer.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-08-2961

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
The ErbB signaling network: receptor heterodimerization in development and cancer
Olayioye, M. A., Neve, R. M., Lane, H. A., & Hynes, N. E. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,489
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591

Show all 31 references

Sorted by citations

Items 101–200 of 291

KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
(2010) · Europe PMC (PubMed Central) · Cited by 43
Novel Chemosensitive Single-Nucleotide Polymorphism Markers to Targeted Regimens in Metastatic Colorectal Cancer
Kim, J. C., Kim, S., Cho, D. H., Ha, Y. J., Choi, E. Y., Kim, C. W., Roh, S. A., Kim, T. W. B., Ju, H., & Kim, Y. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1907 · Cited by 42
Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer
Stefano, A. D. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i29.9732 · Cited by 45
Molecular Predictors of Response to Chemotherapy in Colorectal Cancer
Dienstmann, R., Vilar, E., & Tabernero, J. M. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318212f844 · Cited by 43
New Strategies in Colorectal Cancer: Biomarkers of Response to Epidermal Growth Factor Receptor Monoclonal Antibodies and Potential Therapeutic Targets in Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Pathways
Dasari, A. N., & Messersmith, W. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2283 · Cited by 42
PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis
Wu, S., Gan, Y., Wang, X., Liu, J., Li, M., & Tang, Y. (2013) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-013-1400-x · Cited by 44
Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer.
Lin, J. S., Webber, E. M., Senger, C. A., Holmes, R. S., & Whitlock, E. P. (2011) · PubMed · Cited by 40
Personalized Medicine and Oncology Practice Guidelines: A Case Study of Contemporary Biomarkers in Colorectal Cancer
Kelley, R. K., Bebber, S. L. V., Phillips, K. A., & Venook, A. P. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0004 · Cited by 40
Current and future biomarkers in the treatment of colorectal cancer
Cuyle, P.-J. A., & Prenen, H. (2016) · Acta Clinica Belgica · doi:10.1080/17843286.2016.1262996 · Cited by 40
Self-citation
Targeted Therapies: The Rare Cancer Paradigm
Pierotti, M. A., Negri, T., Tamborini, E., Perrone, F., Pricl, S., & Pilotti, S. (2009) · Molecular Oncology · doi:10.1016/j.molonc.2009.10.003 · Cited by 38
Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer
Izar, B., Rotow, J. K., Gainor, J. F., Clark, J. W., & Chabner, B. A. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007807 · Cited by 38
Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer
Soeda, H., Shimodaira, H., Watanabe, M., Suzuki, T., Gamoh, M., Mori, T., Komine, K., Iwama, N., Kato, S., & Ishioka, C. (2012) · International Journal of Clinical Oncology · doi:10.1007/s10147-012-0422-8 · Cited by 37
Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review)
Libra, M. (2010) · Molecular Medicine Reports · doi:10.3892/mmr.2010.408 · Cited by 37
Predicting Response to EGFR Inhibitors in Metastatic Colorectal Cancer: Current Practice and Future Directions
Shankaran, V., Obel, J. C., & Benson, A. B. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0221 · Cited by 36
Systematic review/Meta-analysis Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients
Huang, L., Liu, Z., Deng, D., Tan, A., Liao, M., Mo, Z., & Yang, X. (2014) · Archives of Medical Science · doi:10.5114/aoms.2014.40728 · Cited by 37
Epidermal Growth Factor Receptor Pathway Mutations and Colorectal Cancer Therapy
Grossmann, A. H., & Samowitz, W. S. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0047-ra · Cited by 33
Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer
Tan, E. S., Fan, W., Knepper, T. C., Schell, M. J., Şahin, İ. H., Fleming, J. B., & Xie, H. (2022) · Targeted Oncology · doi:10.1007/s11523-022-00898-7 · Cited by 32
A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies
Yoshida, M., Shimura, T., Sato, M., Ebi, M., Nakazawa, T., Takeyama, H., & Joh, T. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1340-x · Cited by 31
Integration of Epidermal Growth Factor Receptor Inhibitors with Preoperative Chemoradiation
Debucquoy, A., Machiels, J., McBride, W. H., & Haustermans, K. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1622 · Cited by 32
Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer
Bianchi, A. S., Bencardino, K. B., Nicolantonio, F. D., Pozzi, F., Funaioli, C., Gambi, V., Arena, S., Martini, M., Lamba, S., Cassingena, A., et al. (2010) · Targeted Oncology · doi:10.1007/s11523-010-0138-5 · Cited by 31
Application of molecular techniques in the diagnosis, prognosis and management of patients with colorectal cancer: a practical approach
LeGolvan, M. P., Taliano, R., & Resnick, M. B. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.03.003 · Cited by 32
Individualized therapy for metastatic colorectal cancer
SILVESTRI, A. D., Pin, E., Huijbers, A., Pellicani, R., Parasido, E., Pierobon, M., Petricoin, E. F., Liotta, L. A., & Belluco, C. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12070 · Cited by 31
Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer
Bianchi, A. S., Bencardino, K. B., Cassingena, A., Venturini, F., Funaioli, C., Cipani, T., Amatu, A., Pietrogiovanna, L., Schiavo, R., Nicolantonio, F. D., et al. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70012-8 · Cited by 30
Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity
Ung, N., Putoczki, T. L., Stylli, S. S., Ng, I., Mariadason, J. M., Chan, T. A.-T., Zhu, H., & Luwor, R. B. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28179 · Cited by 30
EGFR signaling in colorectal cancer: a clinical perspective
Frattini, M., Saletti, P., Molinari, F., & Dosso, S. D. (2015) · Gastrointestinal Cancer Targets and Therapy · doi:10.2147/gictt.s49002 · Cited by 32
Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9
E, J., Xing, J., Gong, H., He, J., & Zhang, W. (2015) · Tumor Biology · doi:10.1007/s13277-014-2667-5 · Cited by 29
Development of Molecular Biomarkers in Individualized Treatment of Colorectal Cancer
Mattos‐Arruda, L. D., Dienstmann, R., & Tabernero, J. M. (2011) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2011.03.030 · Cited by 30
Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications
Bumrungthai, S., Munjal, K., Nandekar, S., Cooper, K., Ekalaksananan, T., Pientong, C., & Evans, M. F. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0611-0 · Cited by 29
Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients
Montagut, C. O., Iglesias, M., Arumí, M., Bellosillo, B., Gallén, M., Martinez-Fernandez, A., Martinez-Aviles, L. M., Cañadas, I., Dalmases, A., Moragón, E., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605612 · Cited by 29
Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS
Tural, D. G., Batur, Ş., Erdamar, S., Akar, E., Kepil, N., Mandel, N. M., & Serdengeçti, S. (2013) · Tumor Biology · doi:10.1007/s13277-013-1138-8 · Cited by 28
Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer
Yang, J., Li, S., Wang, B., Wu, Y., Chen, Z., Lv, M., Lin, Y., & Yang, J. (2016) · Tumor Biology · doi:10.1007/s13277-016-5140-9 · Cited by 29
Gastrointestinal tissue‐based molecular biomarkers: a practical categorisation based on the 2019 World Health Organization classification of epithelial digestive tumours
Quezada-Marín, J. I., Lam, A. K.-Y., Ochiai, A., Odze, R. D., Washington, M. K., Fukayama, M., Rugge, M., Klimstra, D. S., Nagtegaal, I. D., Tan, P. H., et al. (2020) · Histopathology · doi:10.1111/his.14120 · Cited by 28
Biomarkers in colorectal cancer
Markman, B., Rodríguez-Freixinós, V., & Tabernero, J. M. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0502-z · Cited by 32
Kras in metastatic colorectal cancer
WICKI, A. N., Herrmann, R., & Christofori, G. (2010) · Swiss Medical Weekly · doi:10.4414/smw.2010.13112 · Cited by 28
Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours
Weidlich, S., Walsh, K., Crowther, D., Burczynski, M. E., FEUERSTEIN, G. Z., CAREY, F. A., Steele, R. J., Wolf, C. R., Miele, G., & Smith, G. C. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.197 · Cited by 27
Strategies for Overcoming Inherent and Acquired Resistance to EGFR Inhibitors by Targeting Downstream Effectors in the RAS/PI3K Pathway
Weickhardt, A. J., Tebbutt, N. C., & Mariadason, J. M. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910793357961 · Cited by 27
Prognostic and predictive markers in liver limited stage IV colorectal cancer
Rehman, A. H., Jones, R. P., & Poston, G. J. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.06.038 · Cited by 27
Current Update of Laboratory Molecular Diagnostics Advancement in Management of Colorectal Cancer (CRC)
Pang, S.-W., Awi, N. J., Armon, S., Lim, W. W.-D., Low, J. S.-H., Peh, K.-B., Peh, S., & Teow, S. (2019) · Diagnostics · doi:10.3390/diagnostics10010009 · Cited by 28
Prognostic significance and targeting of HER family in colorectal cancer
Modjtahedi, H. (2012) · Frontiers in bioscience · doi:10.2741/4110 · Cited by 27
Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy
Llovet, P., Sastre, J., Sanz‐Ortega, J., Bando, I., Ferrer, M., Alfonso, P. G., Donnay, O., Carrato, A., Jiménez, A., Aranda, E., et al. (2015) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-015-0165-0 · Cited by 28
The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer
Bouché, O., Beretta, G. D., Alfonso, P., & Geißler, M. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)00036-8 · Cited by 27
DUSP 4 expression identifies a subset of colorectal cancer tumors that differ in MAPK activation, regardless of the genotype
de Vriendt, V., Roock, W. D., Narzo, A. F. D., Tian, S., Biesmans, B., Jacobs, B., Budínská, E., Sagaert, X., Rossi, S., D’Ario, G., et al. (2013) · Biomarkers · doi:10.3109/1354750x.2013.819038 · Cited by 25
Self-citation
The Challenge of Metastatic Colorectal Cancer
Cidón, E. U. (2010) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s5214 · Cited by 26
Signaling mechanisms of resistance to EGFR- and Anti-Angiogenic Inhibitors cancer
Mirone, G., Shukla, A. K., & Marfè, G. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.012 · Cited by 28
Predictive Molecular Classifiers in Colorectal Cancer
Bohanes, P. O., LaBonte, M. J., Winder, T., & Lenz, H. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.05.012 · Cited by 26
Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
Lu, X., Li, Y., Li, Y., Zhang, X., Shi, J., Feng, H., Yu, Z., & Gao, Y. (2023) · BMC Cancer · doi:10.1186/s12885-023-11600-z · Cited by 30
Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma
Bagadi, S., Sanghvi, M., Nair, S. B., & Das, B. R. (2012) · The International Journal of Biological Markers · doi:10.5301/jbm.2012.9108 · Cited by 25
Relationship Between Colorectal Cancer Biomarkers and Response to Epidermal Growth Factor Receptor Monoclonal Antibodies
Hawkes, E. A., & Cunningham, D. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5626 · Cited by 25
Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist, B. A., Kempa, M., Novy, M., Oberkanins, C., Xu, L., Li, G., Loland, C., & Poetsch, M. (2014) · PubMed Central · Cited by 24
Integrating anti-EGFR therapies in metastatic colorectal cancer.
Haraldsdóttir, S., & Bekaii‐Saab, T. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2013.028 · Cited by 24
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation
Giampieri, R., Scartozzi, M., Prete, M. D., Maccaroni, E., Bittoni, A., Faloppi, L., Bianconi, M., Cecchini, L., & Cascinu, S. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.05.008 · Cited by 24
Patient-Tailored Treatments with Anti-EGFR Monoclonal Antibodies in Advanced Colorectal Cancer: KRAS and Beyond
Ballestrero, A., Garuti, A., Cirmena, G., Rocco, I., Palermo, C., Nencioni, A., Scabini, S., Zoppoli, G. M., Parodi, S., & Patrone, F. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912800190956 · Cited by 24
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.
Wong, N. S., Fernando, N. H., Nixon, A. B., Cushman, S. M., Aklilu, M., Bendell, J. C., Morse, M. A., Blobe, G. C., Ashton, J., Pang, H., et al. (2011) · PubMed · Cited by 25
KRAS Mutation Screening in Colorectal Cancer: From Paper to Practice
Fakih, M. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.003 · Cited by 24
The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors
Wainberg, Z. A., & Drakaki, A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1050375 · Cited by 23
PTEN mRNA expression is less pronounced in left- than right-sided colon cancer: a retrospective observational study
Kuramochi, H., Nakamura, A., Nakajima, G., Kaneko, Y., Araida, T., Yamamoto, M., & Hayashi, K. (2016) · BMC Cancer · doi:10.1186/s12885-016-2400-4 · Cited by 23
An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma
Seeree, P., Pearngam, P., Kumkate, S., & Janvilisri, T. (2015) · International Journal of Genomics · doi:10.1155/2015/179528 · Cited by 22
Survey of KRAS, BRAF and PIK3CA mutational status in 209 consecutive Italian colorectal cancer patients
Bozzao, C., Varvara, D., Piglionica, M., Bagnulo, R., Forte, G., Patruno, M., Russo, S., Piscitelli, D., Stella, A., & Resta, N. (2012) · The International Journal of Biological Markers · doi:10.5301/jbm.2012.9765 · Cited by 23
Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts
Lee, H., Son, E., Lee, K., Lee, Y., Kim, Y., Lee, J.-C., Lim, Y., Hur, M., Kim, D., & Nam, D.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235894 · Cited by 22
The Multidisciplinary Management of Colorectal Cancer: Present and Future Paradigms
Sievers, C. K., Kratz, J. D., Zurbriggen, L. D., LoConte, N. K., Lubner, S. J., Uboha, N., Mulkerin, D. L., Matkowskyj, K. A., & Deming, D. A. (2016) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0036-1584292 · Cited by 22
Personalized treatment for advanced colorectal cancer: KRAS and beyond
Karapetis, C. S., & Patel, G. S. (2013) · Cancer Management and Research · doi:10.2147/cmar.s35025 · Cited by 20
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
Spindler, K. G., Pallisgaard, N., Lindebjerg, J., Kjær‐Frifeldt, S., & Jakobsen, A. K. M. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-107 · Cited by 21
Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS
Liu, J., Xie, L., Cheng, L., Qian, X., Liu, B., Hu, J. Y., Ren, W., & Yang, M. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s86966 · Cited by 21
EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics
Yamamoto, I., Nosho, K., Kanno, S., Igarashi, H., Kurihara, H., Ishigami, K., Ishiguro, K., Mitsuhashi, K., Maruyama, R., Koide, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14863 · Cited by 21
Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review
Merla, A., & Goel, S. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/387172 · Cited by 22
Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on KRAS Mutation Status (T-CORE0801)
Soeda, H., Shimodaira, H., Gamoh, M., Ando, H., Isobe, H., Suto, T., Takahashi, S. I., Kakudo, Y., Amagai, K., Mori, T., et al. (2014) · Oncology · doi:10.1159/000360989 · Cited by 21
Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer
Kim, S. T., Jang, K., Lee, J., Jang, H.-M., Choi, H. J., Jang, H.-L., Park, S. H., Park, Y. S., Lim, H. Y., Kang, W. K., et al. (2015) · Translational Oncology · doi:10.1016/j.tranon.2014.12.003 · Cited by 21
Elucidating the prognostic significance of KRAS , NRAS , BRAF and PIK3CA mutations in C hinese patients with metastatic colorectal cancer
Ma, B. B. Y., Mo, F. K. F., TONG, J. H. M., Wong, C. Y., Wong, S. C. C., Ho, W. M., Wu, Ç., Lam, P. W., Chan, K.-F., Chan, T. S. K., et al. (2015) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12342 · Cited by 20
Treatment Individualization in Colorectal Cancer
van Geel, R. M. J. M., Beijnen, J. H., Bernards, R., & Schellens, J. H. M. (2015) · Current Colorectal Cancer Reports · doi:10.1007/s11888-015-0288-z · Cited by 20
Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview
Lin, P. S., & Semrad, T. J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7765-9_18 · Cited by 20
Monoclonal antibodies for targeted therapy in colorectal cancer.
Banerjee, S., & Flores‐Rozas, H. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.8.11403 · Cited by 21
Recent applications of chemosensitivity tests for colorectal cancer treatment
Yoon, Y. S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i44.16398 · Cited by 19
Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come
Chen, C. T., Bartolomeo, M. D., Corallo, S., Strickler, J. H., & Goyal, L. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280871 · Cited by 18
Biomarkers for Predicting the Efficacy of Anti-Epidermal Growth Factor Receptor Antibody in the Treatment of Colorectal Cancer
Okada, Y., Miyamoto, H., Goji, T., & Takayama, T. (2014) · Digestion · doi:10.1159/000356202 · Cited by 18
Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies
Azuara, D., Santos, C., López‐Doriga, A., Grasselli, J., Nadal, M., Sanjuán, X., Marín, F., Vidal, J., Montal, R., Moreno, V. R., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0820 · Cited by 19
Colorectal Liver Metastases: Does the Future of Precision Medicine Lie in Genetic Testing?
Barbon, C., Margonis, G. A., Andreatos, N., Rezaee, N., Sasaki, K., Buettner, S., Damaskos, C., Pawlik, T. M., He, J. P., Wolfgang, C. L., et al. (2018) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-018-3766-1 · Cited by 18
Gene status of head and neck squamous cell carcinoma cell lines and cetuximab‐mediated biological activities
Kondo, N., Tsukuda, M., Taguchi, T., Nakazaki, K., Sakakibara, A., Takahashi, H., Toth, G., & Nishimura, G. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01999.x · Cited by 17
The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation
Kim, J. S., Kim, J. E., Kim, K., Lee, J., Park, J. O., Lim, H. Y., Park, Y. S., Kang, W. K., & Kim, S. T. (2017) · Journal of Cancer · doi:10.7150/jca.19458 · Cited by 17
The Dark Side of the Moon: The PI3K/PTEN/AKT Pathway in Colorectal Carcinoma
Silvestris, N., Tommasi, S., Petriella, D., Santini, D., Fistola, E., Russo, A. D., Numico, G., Tonini, G., Maiello, E., & Colucci, G. (2009) · Oncology · doi:10.1159/000258498 · Cited by 17
Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02)
García‐Albéniz, X., Alonso, V., Escudero, P., Méndez, M., Gallego-Plazas, J., Rodríguez, J. R., Salud, A., Fernández-Plana, J., Manzano, H., Zanui, M., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0728 · Cited by 16
Highly sensitive detection of the PIK3CA H1047R mutation in colorectal cancer using a novel PCR-RFLP method
Li, W., Hu, T., Zhou, L., Feng, Y., Wang, Y., & Jin, F. (2016) · BMC Cancer · doi:10.1186/s12885-016-2493-9 · Cited by 15
Biomarker-Based Selection of Therapy For Colorectal Cancer
Ross, J. S. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.11.38 · Cited by 14
Primary and acquired resistance to biologic therapies in gastrointestinal cancers
Lubner, S. J., Uboha, N. V., & Deming, D. A. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.01.16 · Cited by 14
Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
Yu, I. S., Aubin, F., Goodwin, R. A., Loree, J. M., Mather, C. A., Sheffield, B. S., Snow, S. L., & Gill, S. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221111705 · Cited by 17
Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA
Chang, L., Chiu, H., Shun, C., Liang, J., Lin, J., Chen, C.-C., Lee, Y., & Wu, M. (2014) · BMC Gastroenterology · doi:10.1186/s12876-014-0221-y · Cited by 14
Hotspot oncomutations: implications for personalized cancer treatment
Myers, M. B., Wang, Y., McKim, K. L., & Parsons, B. L. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.51 · Cited by 14
The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer.
Muhammad, S., Jiang, Z., Liu, Z., Kaur, K., & Wang, X. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2012.044 · Cited by 13
KRAS Testing and Its Importance in Colorectal Cancer
Patil, D. T., Fraser, C. R., & Plesec, T. P. (2010) · Current Oncology Reports · doi:10.1007/s11912-010-0099-y · Cited by 13
Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy inKRASWild-Type Patients
Er, T., Chen, C.-C., Bujanda, L., & Herreros‐Villanueva, M. (2014) · BioMed Research International · doi:10.1155/2014/591867 · Cited by 13
Review Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer
Krawczyk, P. A., & Kowalski, D. M. (2014) · Współczesna Onkologia · doi:10.5114/wo.2013.38566 · Cited by 13
Mutation of the PIK3CA gene as a prognostic factor in patients with colorectal cancer
Stec, R., Semeniuk-Wojtaś, A., Charkiewicz, R., Bodnar, L., Korniluk, J., Smoter, M., Chyczewski, L., Nikliński, J., & Szczylik, C. A. (2015) · Oncology Letters · doi:10.3892/ol.2015.3398 · Cited by 13
Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants
Ghodsinia, A., Lego, J.-A. M. T., & Garcia, R. L. (2020) · Cells · doi:10.3390/cells9051116 · Cited by 13
Anticancer therapeutics: a brief account on wide refinements.
Rehman, F. U., Al-Waeel, M., Naz, S. S., & Shah, K. U. (2020) · PubMed Central · Cited by 12
Prevalence and prognostic role of PIK3CA E545K mutation in Iranian colorectal cancer patients.
Ranjbar, R., Mohammadpour, S., Esfahani, A. T., Namazian, S., Taleghani, M. Y., Baghaei, K., Mortazavi‐Tabatabaei, S. A., Pasharavesh, L., & Mojarad, E. N. (2019) · Gastroenterology and hepatology from bed to bench. · Cited by 11
Targeting EGFR in Metastatic Colorectal Cancer Beyond the Limitations of KRAS Status: Alternative Biomarkers and Therapeutic Strategies
Caiazza, F., Elliott, L., Fennelly, D. W., Sheahan, K. D., Doherty, G. A., & Ryan, E. J. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.5 · Cited by 13
Combined assessment of the TNM stage and BRAF mutational status at diagnosis in sporadic colorectal cancer patients
Sayagués, J. M., del Carmen, S., Abad, M., Corchete, L. A., Bengoechea, Ó., Anduaga, M. F., Baldeón, M. J., Cruz, J. J., Alcázar, J. A. S., Angoso, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25300 · Cited by 11
Impact of molecular markers on treatment selection in advanced colorectal cancer
Prenen, H., Tejpar, S., & Cutsem, E. V. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70018-8 · Cited by 11
Self-citation
Multigene Assays in Metastatic Colorectal Cancer
Deeb, K. K., Sram, J. P., Gao, H., & Fakih, M. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0221 · Cited by 10
Select Biomarkers for Tumors of the Gastrointestinal Tract: Present and Future
Bartley, A. N., & Hamilton, S. R. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0189-ra · Cited by 9
Mechanism of EGER-related cancer drug resistance
Wei, X. (2011) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32834a149c · Cited by 9

Authors: Prenen, H., De Schutter, J., Jacobs, B., De Roock, W., Biesmans, B., Claes, B., Lambrechts, D., Van Cutsem, E., & Tejpar, S.
Affiliations: 1Department of Digestive Oncology, University Hospital Gasthuisberg,
2Center for Human Genetics K.U.Leuven, and
KU Leuven (BE)
ORCID: Prenen, Hans
Lambrechts, Diether
Tejpar, Sabine
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2009-04-30
Volume: 15
Issue: 9
Pages: 3184-3188
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-08-2961
OpenAlex: W2028035144
Cited by: 291
References: 31
Citations by year: 2025: 1 · 2024: 6 · 2023: 4 · 2022: 3 · 2021: 1 · 2020: 8 · 2019: 7 · 2018: 6 · 2017: 8 · 2016: 20 · 2015: 23 · 2014: 31 · 2013: 34 · 2012: 34
FWCI: 22.99
Type: journal article
Language: en
Open access: closed
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: PIK3CA mutation, cetuximab, EGFR inhibitors, metastatic colorectal cancer, KRAS mutation, PI3K/Akt signaling, drug resistance, irinotecan, predictive biomarkers, chemorefractory cancer
MeSH terms: Cetuximab, Irinotecan, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Humans, Male, Middle Aged, Mutation, Neoplasm Staging, Prognosis, Proto-Oncogene Proteins, Colorectal Neoplasms, Cohort Studies, Survival Rate, Proto-Oncogene Proteins p21(ras), Treatment Outcome, ras Proteins, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Maximum Tolerated Dose, Class I Phosphatidylinositol 3-Kinases, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks